We are a San Francisco based biotech-focused investment fund. Come forge the future of biotech with us.
Portfolio 69
| Date | Name | Website | Total Raised | Location |
| 17.05.2024 | BridgeBio ... | bridgebio.com | $434.2M | United Sta... |
| 17.05.2024 | ATTOVIA | attovia.com | $105M | - |
| 08.11.2023 | Terremoto ... | terremotobio.com | $175M | - |
| 08.11.2023 | Paratus Sc... | paratussciences.com | - | United Sta... |
| 08.11.2023 | MorphImmun... | morphimmune.com | $17.1M | United Sta... |
| 25.06.2023 | Epikast | epikast.com | - | - |
| - | ArtivaBio | artivabio.com | $198M | United Sta... |
| - | Ashvattha ... | avttx.com | $69M | United Sta... |
| - | Relay* | relaytx.com | $463M | - |
| - | Syndax | syndax.com | $152.6M | - |
Show more
Persons 17
| Date | First Name | Last Name | Title | Location | |||
| - | Alex | Tkachenko | Executive ... | linkedin.c... | - | - | - |
| - | Sarah | Spencer | PRINCIPAL | linkedin.c... | - | - | - |
| - | Brad | Prosek | Operating ... | linkedin.c... | - | - | - |
| - | Scott | Perlen | CFO | linkedin.c... | - | - | - |
| - | Catherine | McWilliams | Director o... | linkedin.c... | - | - | - |
| - | Miranda | Fornaro | Operations... | linkedin.c... | - | - | - |
| - | Basheer | Zada | PRINCIPAL | linkedin.c... | - | - | - |
| - | Kristin | Fabianski | Chief of S... | linkedin.c... | - | - | - |
| - | Caroline | Stout | Partner | linkedin.c... | - | - | - |
| - | Whan | Lee | Analyst | linkedin.c... | - | - | - |
Show more
Mentions in press and media 3
| Date | Title | Description |
| 28.10.2020 | Ally Bridge Portfolio News – Nuvation Bio and Panacea Announce Business Combination Agreement, Creating a Publicly Listed Leader in Oncology Drug Development | NEW YORK – – October 21, 2020 – Nuvation Bio, Inc., a biopharmaceutical company focused on revolutionizing cancer treatment by discovering, developing and delivering therapies that tackle some of the greatest needs in oncology, and Panacea ... |
| 10.08.2015 | Daily funding roundup - August 10, 2015 | Editas Medicine Inc secured $120M; Turing Pharmaceuticals bagged $90M; Vainglory raised $26M Editas Medicine Inc. raised $120 million from investors to support development of a technology that can precisely edit DNA and potentially treat fa... |
| 10.08.2015 | Genome editing company Editas gets infused with $120M | Investors in the company include Google Ventures, Khosla Ventures and Bill Gates We like to complain about the world a lot, but this really is such a cool time to be alive. We are coming up with amazing technology at a more rapid pace than ... |